Duplicate Document
This document appears to be a copy. The original version is:
EFTA Document EFTA01447256Case File
efta-efta01447256DOJ Data Set 10CorrespondenceEFTA Document EFTA01447256
Date
Unknown
Source
DOJ Data Set 10
Reference
efta-efta01447256
Pages
0
Persons
0
Integrity
Loading PDF viewer...
Summary
Ask AI About This Document
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
As of 5/8/14 2:10 pm
Description
Trade Date
Quantity
Current Price
Unit Cost
Market Value
Current Total Cost
Unrealized G/L
SANGAMO BIOSCIENCES
5/28/2013
50,000.00
$
12.17
$
8.44
$
608,500.00
422,214.00
186,286.00
BIOGEN
2/14/2012
2,095.00
$
285.28
$
119.55
$
597,661.60
250,454.95 $
347,206.65
FOUNDATION MEDICINE
1/13/2014
25,000.00
$
24.13
$
27.51
$
603,250.00
687,663.50
S
(84,413.50)
GILEAD SCIENCES INC
Multiple
8,100.00
$
79.36
$
79.41
$
642,816.00
643,204.00 $
(388.00)
Total Biotech
$
2,452,227.60
$
2,003,536.45
$
448,691.15
ARIAD PHARMACEUTICALS
Multiple
16,535.00
$
6.76
$
17.60
$
111,776.60
290,997.40 $
(179,220.80)
PX_LAST
CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e)
CONFIDENTIAL
DB-SDNY-0101837
SDNY_GM_00248021
EFTA01447256
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.
Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.